Stock analysts at Evercore ISI assumed coverage on shares of Icon (NASDAQ:ICLR) in a report released on Thursday, The Fly reports. The firm set an “outperform” rating on the medical research company’s stock.
Other analysts have also issued research reports about the company. KeyCorp reiterated a “buy” rating and issued a $130.00 price target on shares of Icon in a report on Thursday, January 11th. Zacks Investment Research lowered Icon from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. ValuEngine lowered Icon from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Jefferies Group boosted their price target on Icon from $122.00 to $132.00 and gave the company a “buy” rating in a report on Monday, October 9th. Finally, Barclays boosted their price target on Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Icon presently has an average rating of “Buy” and a consensus target price of $121.82.
Shares of Icon (ICLR) traded up $0.59 during trading hours on Thursday, hitting $112.88. The company’s stock had a trading volume of 319,600 shares, compared to its average volume of 286,355. Icon has a fifty-two week low of $76.46 and a fifty-two week high of $124.48. The stock has a market capitalization of $6,050.00, a price-to-earnings ratio of 21.92, a PEG ratio of 1.60 and a beta of 0.61. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31.
Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. The firm had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. Icon had a return on equity of 28.42% and a net margin of 16.37%. Icon’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.19 earnings per share. analysts expect that Icon will post 5.37 earnings per share for the current fiscal year.
A number of large investors have recently modified their holdings of ICLR. SG Americas Securities LLC acquired a new position in shares of Icon during the third quarter worth $148,000. Commonwealth Equity Services Inc acquired a new position in shares of Icon during the third quarter worth $208,000. Holderness Investments Co. acquired a new position in shares of Icon during the third quarter worth $216,000. IHT Wealth Management LLC increased its position in shares of Icon by 16.9% during the second quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock worth $223,000 after purchasing an additional 24 shares in the last quarter. Finally, Murphy Capital Management Inc. acquired a new position in shares of Icon during the third quarter worth $239,000. 89.66% of the stock is owned by institutional investors.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.